Mobile

This is a research study to treat patients who have gout flares with a study medicine called canakinumab or triamcinolone acetonide, that has been previously approved to treat gout flares

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-024173-39

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To confirm that canakinumab 150 mg s.c. administered as pre-filled syringe (PFS) is superior to triamcinolone acetonide 40 mg i.m with respect to patient’s assessment of acute gouty arthritis pain intensity in the joint most affected at randomization measured after 72 hours (on a 0-100 mm VAS)

Critère d'inclusion

  • Treatment of acute gouty arthritis flares in frequently flaring patients

Liens